AI and Sustainability: Akkodis showcases the future of sustainable and digital innovation at the Paris Air Show 2025
PARIS, June 5, 2025 /PRNewswire/ — Akkodis, a global digital engineering company and part of the Adecco Group, presents innovations to integrate AI and sustainability in the aviation, aerospace and defense sectors at the world-famous 55th Paris Air Show at the Le Bourget Parc des Expositions.
Visitor experience
With more than four decades of expertise in engineering, research & development (ER&D), Akkodis will offer visitors to its Chalet (#303 – line B) an experiential and immersive journey, an inspiring conference program and two expert publications on the topic of augmented engineering, as well as inclusion and diversity in engineering. The Chalet also features an AI Path and a Sustainability area, showcasing Akkodis' 360-degree product lifecycle capabilities, from ER&D to manufacturing and operations, IT and ecosystem support.
'Akkodis is sending a powerful message to the industry by bringing its full capacity to the Paris Air Show 2025 to showcase its pioneering technologies. We are here to help our clients in the aviation, aerospace and defense sector to unlock their full potential with the best tech consultants and ER&D solutions. As a trusted partner, our clients can count on our deep expertise and game-changing solutions to realize their ambition. We are committed to leveraging our full tech partnership ecosystem to support our clients in their value creation efforts', comments Jo Debecker, President and CEO of Akkodis.
AI Path & Sustainability Area
The event embodies excellence, innovation, and international cooperation in the fields of aviation and space. Following the idea of the 55th edition of Paris Air Show to serve as a global meeting place for excellence and innovation, Akkodis is putting the spotlight on two major pillars of transformation in the sector:
– The integration of AI for performance through an interactive animation illustrating an optimization solution for aircraft maintenance, a helicopter cockpit simulator that makes it easier for pilots to get started, and a demonstration of a drone surveillance mission in the metaverse.
– The challenge of a sustainable industry – Manufacturers are not only focused on the decarbonisation of aviation, but also in the green and responsible evolution of their entire value chain, supply chain and organisation. These issues will be highlighted through several scale models of devices, 3D models and animations on tablets.
Akkodis is leveraging its strong technology ecosystem at the show. For example, attendees will learn how Akkodis and our global technology partner Microsoft are using AI technology to unlock solutions for the sector.
'In our second appearance at the Paris Air Show under the Akkodis brand, I am very proud to present the expertise and innovative spirit that our 9.000 employees in France demonstrate on a daily basis – they are shaping a more efficient, more connected and more sustainable future of aeronautics, aerospace and defense throughout the value chain. The Akkodis DNA is historically linked to these three industries and the technological innovations presented this year at the Paris Air Show are direct responses needed to support them in their transformation', says Yves-Marie BOISSONNET, President France and South EMEA Akkodis.
Media contacts
Anne Friedrich SVP, Global Head of Communications, Akkodis E. anne.friedrich@adeccogroup.com
Ariane Olleris Manager External Communications The Adecco GroupE. ariane.olleris@adeccogroup.com
About Akkodis
Akkodis is a global digital engineering company and Smart Industry leader. We enable clients to advance in their digital transformation with Consulting, Solutions, Talent, and Academy services. Headquartered in Switzerland and part of the Adecco Group, Akkodis is a trusted tech partner to the world's industries. We co-create and pioneer solutions that help to solve major challenges, from accelerating the clean energy transition and green mobility, to improving user and patient centricity. Empowered by a culture of inclusion and diversity, our 50,000 tech experts across 30 countries combine best-in-class technologies and cross industry knowledge to drive purposeful innovation for a more sustainable tomorrow. We are passionate about Engineering a Smarter Future Together. akkodis.com | LinkedIn | Instagram | Facebook Twitter
About the Adecco Group
The Adecco Group is the world's leading talent company. Our purpose is making the future work for everyone. Through our three global business units – Adecco, Akkodis and LHH – across 60 countries, we enable sustainable and lifelong employability for individuals, deliver digital and engineering solutions to power the Smart Industry transformation and empower organisations to optimise their workforces. The Adecco Group leads by example and is committed to an inclusive culture, fostering sustainable employability, and supporting resilient economies and communities. The Adecco Group AG is headquartered in Zurich, Switzerland (ISIN: CH0012138605) and listed on the SIX Swiss Exchange (ADEN). www.adeccogroup.com
Photo – https://mma.prnewswire.com/media/2702592/Paris_Air_Show.jpgLogo – https://mma.prnewswire.com/media/2598662/5351883/Akkodis_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/ai-and-sustainability-akkodis-showcases-the-future-of-sustainable-and-digital-innovation-at-the-paris-air-show-2025-302473490.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
6 hours ago
- Malaysian Reserve
Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034)
The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics, and greater investment in research and development. Along with these, the launch of emerging therapies such as DATROWAY, PADCEV, BNT327/ PM8002, and others will fuel the TNBC market growth. LAS VEGAS, July 29, 2025 /PRNewswire/ — DelveInsight's Triple-Negative Breast Cancer Market Insights report includes a comprehensive understanding of current treatment practices, triple-negative breast cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Triple-Negative Breast Cancer Market Report According to DelveInsight's analysis, the market size for triple-negative breast cancer was found to be USD 4.5 billion in the 7MM in 2024. The United States accounted for the highest market size of TNBC, approximately 69% of the total market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. As per the estimates, among the current treatment options, KEYTRUDA (pembrolizumab) and chemotherapy held the largest TNBC treatment market share, generating approximately USD 2 billion in revenue in 2024 across the 7MM. In 2024, 7MM recorded approximately 104K new TNBC cases. With a projected CAGR of 0.7%, the number of cases is expected to gradually rise, leading to a higher disease burden by 2034. Leading triple-negative breast cancer companies developing emerging therapies, such as AstraZeneca, Daiichi Sankyo, Astellas Pharma, Pfizer, Galera Therapeutics, BioNTech, and others, are developing new TNBC treatment drugs that can be available in the triple-negative breast cancer market in the coming years. The promising triple-negative breast cancer therapies in the pipeline include DATROWAY (Datopotamab Deruxtecan), PADCEV (Enfortumab vedotin), Tilarginine, BNT327/PM8002, IMFINZI (Durvalumab), and others. Discover the TNBC new treatment @ New Treatments for TNBC Triple-Negative Breast Cancer Market Dynamics The triple-negative breast cancer market dynamics are expected to change in the coming years. Combining chemotherapy, immunotherapy, and targeted therapies, such as TALZENNA and TRODELVY, offers enhanced disease control and expands treatment options for advanced-stage TNBC patients, while innovations in immune checkpoint inhibitors, therapeutic vaccines, and ongoing research into personalized approaches are transforming long-term management by boosting immune response, improving survival rates, and addressing the need for more effective, tailored solutions beyond first-line therapy As potential therapies are being investigated for the treatment of triple-negative breast cancer, it is safe to predict that the treatment space will significantly impact the triple-negative breast cancer market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the triple-negative breast cancer market in the 7MM. However, several factors may impede the growth of the triple-negative breast cancer market. TNBC is the most difficult breast cancer subtype to manage due to its aggressive nature, lack of targeted treatment options, and high rates of chemotherapy resistance, which contribute to frequent relapse, reduced treatment efficacy, and limited long-term remission, even when diagnosed early; this underscores the urgent need for innovative, effective therapies that not only improve outcomes and prevent disease progression but also minimize the significant side effects of current aggressive treatments like chemotherapy and immunotherapy, which severely impact patient quality of life. Moreover, triple-negative breast cancer treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the triple-negative breast cancer market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the triple-negative breast cancer market growth. Triple-Negative Breast Cancer Treatment Market Triple-negative breast cancer lacks expression of hormone receptors and HER2, rendering it unresponsive to endocrine and HER2-targeted therapies. Consequently, systemic chemotherapy has long been the mainstay of treatment, especially in metastatic settings. Management typically starts with neoadjuvant or adjuvant chemotherapy, progressing to first-line treatments in advanced stages. If the disease advances or shows inadequate response, additional lines of therapy are introduced. Immunotherapies, particularly PD-1/PD-L1 inhibitors, are increasingly being utilized in metastatic TNBC to boost the body's immune defense against cancer cells. In early-stage TNBC, the PD-1 inhibitor KEYTRUDA (pembrolizumab) has become a standard part of treatment. It is administered with neoadjuvant chemotherapy and then continued as adjuvant monotherapy. In PD-L1-positive patients (CPS ≥10), it is also used alongside chemotherapy for locally recurrent or metastatic disease. Targeted therapies are making headway as well, particularly for patients with BRCA mutations. In such cases, PARP inhibitors like LYNPARZA (olaparib) and TALZENNA (talazoparib) target defective DNA repair pathways. TRODELVY (sacituzumab govitecan), an antibody-drug conjugate (ADC) targeting TROP-2, is approved for relapsed or treatment-resistant metastatic TNBC. Although TECENTRIQ (atezolizumab) was withdrawn from the U.S. market after failing confirmatory trials, it is still available in Europe and Japan. Taxane-based chemotherapy continues to be a cornerstone of TNBC treatment and is often combined with immune checkpoint inhibitors in PD-L1-positive cases. Platinum-based chemotherapy, though occasionally used, has shown mixed results due to concerns over toxicity and limited benefit. Despite therapeutic progress, TNBC remains a particularly aggressive subtype, underscoring the urgent need for continued innovation. Overall, current treatments frequently fall short of achieving lasting disease control, highlighting the pressing demand for novel therapies that can improve long-term outcomes and survival for TNBC patients. To know more about FDA-approved drugs for TNBC, visit @ Approved TNBC Treatment Triple-Negative Breast Cancer Pipeline Therapies and Key Companies Some of the drugs in the pipeline include DATROWAY [(Datopotamab Deruxtecan), AstraZeneca and Daiichi Sankyo], IMFINZI [(Durvalumab), AstraZeneca], PADCEV [(Enfortumab vedotin), Astellas Pharma and Pfizer], Tilarginine [(L-NMMA), Galera Therapeutics], and others. Datopotamab deruxtecan (Dato-DXd), also known as DATROWAY, is an experimental antibody-drug conjugate (ADC) being evaluated for the treatment of triple-negative breast cancer, both as a standalone therapy and in combination with IMFINZI (durvalumab). The therapy is aimed at high-risk TNBC patients, including those who are PD-L1-positive. Results from pivotal Phase III trials are expected in 2025, with more comprehensive findings anticipated by 2026, potentially influencing future treatment approaches for TNBC. Currently in Phase III development for TNBC, Dato-DXd is part of a global collaboration between AstraZeneca and Daiichi Sankyo, initiated in July 2020. Under this partnership, Daiichi Sankyo retains exclusive rights in Japan and oversees manufacturing and supply, while both companies are co-developing the drug across several cancer types globally. Tilarginine (L-NMMA), a broad nitric oxide synthase (NOS) inhibitor, is under Phase II investigation for metaplastic breast cancer (MpBC) in combination with alpelisib and nab-paclitaxel in HER2-negative metastatic or locally advanced settings. It is also being explored with a taxane in Phase II trials for patients with metastatic or locally advanced TNBC. In December 2024, Galera Therapeutics acquired Nova Pharmaceuticals. IMFINZI (durvalumab), an FDA-approved PD-L1 inhibitor developed by AstraZeneca for other cancers, works by blocking PD-L1 to enhance immune system recognition and destruction of tumor cells. It is currently undergoing Phase I/II studies in combination with paclitaxel and other novel therapies as a first-line option for metastatic TNBC (mTNBC), with key data expected by late 2025. Notably, the BEGONIA trial (October 2023) reported durable and significant tumor responses from the combination of datopotamab deruxtecan and IMFINZI when used as a first-line treatment for patients with mTNBC, along with a favorable safety profile. The anticipated launch of these emerging therapies are poised to transform the triple-negative breast cancer market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the triple-negative breast cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. Discover more about triple-negative breast cancer drugs in development @ Triple-Negative Breast Cancer Clinical Trials Recent Developments in the Triple-Negative Breast Cancer Market In May 2025, Gilead Sciences, Inc. reported that TRODELVY (sacituzumab govitecan-hziy) combined with KEYTRUDA (pembrolizumab) lowered the risk of disease progression or death by 35% (hazard ratio: 0.65) compared to the standard treatment of Keytruda plus chemotherapy as a first-line therapy for patients with PD-L1–positive (CPS ≥10) metastatic triple-negative breast cancer (TNBC). In May 2025, Gilead Sciences, Inc. reported positive topline results from the Phase 3 ASCENT-03 trial evaluating TRODELVY (sacituzumab govitecan-hziy). The study achieved its primary goal by showing a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy in patients with first-line metastatic triple-negative breast cancer (mTNBC) who are not eligible for PD-1/PD-L1 inhibitors, either due to being PD-L1 negative or otherwise unsuitable for immunotherapy. In December 2024, Galera Therapeutics completed the acquisition of Nova Pharmaceuticals. Triple-Negative Breast Cancer Overview Triple-negative breast cancer is a particularly aggressive and diverse form of breast cancer that lacks expression of estrogen receptors (ER), progesterone receptors (PR), and HER2. It accounts for a substantial share of breast cancer cases and is associated with fast disease progression, high chances of recurrence, and unfavorable outcomes. TNBC tends to occur more frequently in younger women, individuals of African American descent, and those with BRCA1 gene mutations. The risk factors for TNBC are divided into two categories: non-modifiable factors, such as age, gender, genetic mutations, family history, and breast density, and modifiable ones, which include obesity, exposure to certain chemicals, and specific drug use. Due to its aggressive behavior and absence of hormone receptors, TNBC is particularly difficult to treat, highlighting the need for continuous research to enhance therapeutic approaches and patient survival. Diagnosis typically involves imaging tools like mammography, ultrasound, and MRI, followed by tissue sampling techniques including core needle biopsy, fine needle aspiration, or surgical biopsy. TNBC tumors are often high-grade and poorly differentiated, and the disease is staged using the TNM system, which evaluates tumor size, lymph node involvement, and the extent of metastasis. Triple-Negative Breast Cancer Epidemiology Segmentation The triple-negative breast cancer epidemiology section provides insights into the historical and current triple-negative breast cancer patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The triple-negative breast cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Incident Cases of Breast Cancer Total Incident Cases of TNBC Gene Mutation-specific Incident Cases of TNBC Stage-specific Incident Cases of TNBC Age-specific Incident Cases of TNBC Line-wise Treated Incident Cases of TNBC Triple-Negative Breast Cancer Market Report Metrics Details Study Period 2020–2034 Coverage 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Triple-Negative Breast Cancer Market CAGR 4.7 % Triple-Negative Breast Cancer Market Size in 2024 USD 4.5 Billion Key Triple-Negative Breast Cancer Companies AstraZeneca, Daiichi Sankyo, Astellas Pharma, Pfizer, Galera Therapeutics, BioNTech, Merck, Gilead Sciences, Roche, Genentech, and others Key Triple-Negative Breast Cancer Therapies DATROWAY (Datopotamab Deruxtecan), PADCEV (Enfortumab vedotin), Tilarginine, BNT327/PM8002, IMFINZI (Durvalumab), KEYTRUDA, TRODELVY, TALZENNA, LYNPARZA, TECENTRIQ, and others Scope of the Triple-Negative Breast Cancer Market Report Therapeutic Assessment: Triple-Negative Breast Cancer current marketed and emerging therapies Triple-Negative Breast Cancer Market Dynamics: Key Market Forecast Assumptions of Emerging Triple-Negative Breast Cancer Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Triple-Negative Breast Cancer Market Access and Reimbursement Download the report to understand which factors are driving triple-negative breast cancer market trends @ Triple-Negative Breast Cancer Market Forecast Table of Contents 1 Key Insights 2 Report Introduction 3 TNBC Market Overview at a Glance 3.1 Market Share (%) Distribution of TNBC by Therapies in the 7MM in 2020 3.2 Market Share (%) Distribution of TNBC by Therapies in the 7MM in 2034 4 Executive Summary 5 Key Events 6 Disease Background and Overview 6.1 Introduction 6.2 Various Subtypes of Breast Cancer Based on Immunohistochemical Expression 6.3 TNBC Overview 6.3.1 Intrinsic Molecular Subtypes in TNBC 6.3.2 Characteristics of Tumor Microenvironment in TNBC 6.3.3 Potential Risk Factors 6.3.4 Clinical Presentation 6.3.5 Characterization of HER2-low Breast Cancers 6.4 Diagnosis 6.4.1 Staging 6.4.2 Grading 6.4.3 Clinical Prognostic Stage 6.4.4 Pathological Prognostic Stage 6.4.5 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer 6.4.6 Recommendations for HER2 Testing in Breast Cancer: American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Clinical Practice Guideline Update 6.4.7 Diagnostic Algorithm 6.5 Treatment and Management 6.5.1 NCCN Clinical Practice Guidelines in Oncology for Breast Cancer 6.5.2 ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Early Breast Cancer 6.5.3 ESMO Clinical Practice Guideline for the Diagnosis, Staging, and Treatment of Patients with Metastatic Breast Cancer 6.5.4 Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for Breast Cancer – 2022 Update 6.5.5 Treatment Algorithm 7 Epidemiology and Market Forecast Methodology 8 Epidemiology and Patient Population 8.1 Key Findings 8.2 Assumptions and Rationale: 7MM 8.2.1 Incident Cases of Breast Cancer 8.2.2 Incident Cases of TNBC 8.2.3 Gene Mutation-specific Incident Cases of TNBC 8.2.4 Stage-specific Incident Cases of TNBC 8.2.5 Age-specific Incident Cases of TNBC 8.3 Total Incident Cases of Breast Cancer in the 7MM 8.4 Total Incident Cases of TNBC in the 7MM 8.5 The United States 8.6 EU4 and the UK 8.7 Japan 9 Patient Journey 10 Marketed Therapies 10.1 Key Cross Competition 10.2 KEYTRUDA (pembrolizumab): Merck 10.2.1 Product Description 10.2.2 Regulatory Milestone 10.2.3 Other Developmental Activities 10.2.4 Clinical Trials Information 10.2.5 Safety and Efficacy 10.3 TRODELVY (sacitzumab govitecan-hziy): Gilead Sciences 10.4 TALZENNA (talazoparib): Pfizer 10.5 LYNPARZA (olaparib): AstraZeneca/Merck 10.6 TECENTRIQ (atezolizumab): Roche/Genentech To be continued in the report… 11 Emerging Drug Profiles 11.1 Key Cross Competition of Emerging Drugs 11.2 DATROWAY (Datopotamab Deruxtecan): AstraZeneca/Daiichi Sankyo 11.2.1 Drug Description 11.2.2 Other Developmental Activities 11.2.3 Clinical Trials Information 11.2.4 Safety and Efficacy 11.2.5 Analysts' View 11.3 PADCEV (Enfortumab vedotin): Astellas Pharma/Pfizer 11.4 Tilarginine: Galera Therapeutics 11.5 BNT327/PM8002: BioNTech 11.6 IMFINZI (Durvalumab): AstraZeneca To be continued in the report… 12 TNBC: Market Analysis 12.1 Key Findings 12.2 Market Outlook 12.3 Attribute Analysis 12.4 Key Market Forecast Assumptions 12.4.1 Cost Assumptions and Rebates 12.4.2 Pricing Trends 12.4.3 Analogue Assessment 12.4.4 Launch Year and Therapy Uptake 12.5 Total Market Size of TNBC in the 7MM 12.6 Market Size of TNBC by Therapies in the 7MM 12.7 Market Size of TNBC in the United States 12.8 Market Size of TNBC in EU4 and the UK 12.9 Market Size of TNBC in Japan 13 Key Opinion Leaders' Views 14 Unmet Needs 15 SWOT Analysis 16 Market Access and Reimbursement 16.1 The United States 16.2 In EU4 and the UK 16.3 Japan 17 Acronyms and Abbreviations 18 Bibliography 19 Report Methodology Related Reports PD-L1 Inhibitors Market PD-L1 Inhibitors Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PD-L1 inhibitors companies including EQRX, CSTONE PHARMACEUTICALS, PFIZER, NOVARTIS, ARCUS BIOSCIENCES, AGENUS, TRACON PHARMACEUTICALS, SHANGHAI HENLIUS BIOTECH, INCYTE CORPORATION, among others. PARP Inhibitors Market PARP Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PARP inhibitors companies including AstraZeneca, Merck, Janssen, Pfizer, Astellas, Pharma& Schweiz, AtlasMedx, AbbVie, GlaxoSmithKline, Pfizer, BeiGene, Allarity Therapeutics, among others. Triple-Negative Breast Cancer Pipeline Triple-Negative Breast Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TNBC companies, including G1 Therapeutics, Inc., Gilead Sciences, Biotheus Inc., GlaxoSmithKline, AstraZeneca, Shanghai Jiaolian Drug Research and Development Co., Ltd, Coherent Biopharma, Daiichi Sankyo Company, Merck, SynDevRx, Inc., Treadwell Therapeutics, AstraZeneca, Novartis Pharmaceuticals, NEC Corporation, Cardiff Oncology, Ocellaris Pharma, Inc., Nuvation Bio Inc., Phoenix Molecular Designs, Pure Biologics S.A., Pure Biologics S.A., Mersana Therapeutics, Zumutor Biologics Inc., Tubulis GmbH, Hinova Pharmaceuticals, Primevax, ARCE Therapeutics, HC Biopharma, Casinvent, among others. Breast Cancer Market Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key breast cancer companies including Veru, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Genentech, Daiichi Sankyo, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur [email protected] + Logo: View original content:
Malaysian Reserve
6 hours ago
- Malaysian Reserve
Humane World for Animals delivers over 195,000 signatures to Target demanding action on animal welfare commitments
Advocates gathered outside of Target headquarters to urge the retailer to follow through on decade-long promises to reduce animal suffering MINNEAPOLIS, July 29, 2025 /PRNewswire/ — Today Humane World for Animals, formerly called the Humane Society of the United States, delivered more than 195,000 signatures in person to Target's downtown Minneapolis headquarters, calling on the company to fulfill its long-overdue commitments to eliminate the extreme confinement of pigs and hens in its supply chain. In 2012, Target pledged to stop sourcing pork from farms that confine pregnant pigs in gestation crates so small they are unable to even turn around. Then in 2016, the company committed to selling only cage-free eggs by 2025. Yet, despite making these pledges more than a decade ago, Target has failed to deliver on either promise. During the petition event, speakers, advocates and supporters from Humane World for Animals delivered 15 large boxes of signed petitions alongside life-sized battery cages stuffed with replica chickens. Dozens of members of the public engaged with the advocates and expressed support for Target's transition to selling eggs and pork sourced from chickens and pigs who are not forced to suffer in extreme confinement. Meanwhile, a mobile billboard circled downtown Minneapolis urging the public to visit the campaign website, 'We delivered a critical message to Target backed by more than 195,000 consumers: extreme confinement of farm animals is not only cruel but completely unnecessary,' said Kent Stein, corporate policy specialist at Humane World for Animals and one of the event's speakers. 'We urge Target to listen to its customers and follow through on long overdue promises to eliminate animal cruelty in its supply chain. We know they can do better just like all the large corporations who have already made, kept and implemented their commitments to animal welfare.' On a typical egg factory farm, hens are crammed into barren wire cages where they endure a lifetime of captivity in a space smaller than a single letter-sized sheet of paper. Pregnant pigs confined in horrific gestation crates suffer from muscle and bone deterioration as well as severe distress, gnawing on the bars of their small cages until their mouths bleed. 'More than a decade has passed since Target made these commitments, yet millions of animals in its supply chain are still suffering in tiny cages,' said Aaron Zellhoefer, Minnesota state director at Humane World for Animals and a featured speaker at the event. 'While many high-profile companies have already made good on their commitments—including Minnesota-based General Mills—Target continues to fall behind. Stop stalling. The time for action is now.' Fourteen states have already banned one or both of forms of extreme confinement for egg-laying hens and pregnant pigs, and hundreds of major companies—including Amazon, McDonald's, Costco, Unilever and Nestlé—have adopted similar policies within their U.S. operations. To learn more and take action visit Download Photos/Videos of today's event Download Photos/Videos of animals in gestation crates and battery cages About Humane World for Animals Together, we tackle the root causes of animal cruelty and suffering to create permanent change. With millions of supporters and work happening in over 50 countries, Humane World for Animals—formerly called the Humane Society of the United States and Humane Society International—addresses the most deeply entrenched forms of animal cruelty and suffering. As the leading voice in the animal protection space, we work to end the cruelest practices, care for animals in crisis and build a stronger animal protection movement. Driving toward the greatest global impact, we aim to achieve the vision behind our name: a more humane world.
Malaysian Reserve
8 hours ago
- Malaysian Reserve
Rejuva Fresh® Unveils New Upgrades for Custom CORE™ 8D, a Revolutionary Aesthetic Laser Platform Designed to Transform In-Office Treatments
ELLSWORTH, Maine, July 29, 2025 /PRNewswire/ — Rejuva Fresh®, a U.S.-based innovator of wellness and aesthetic technology, and a worldwide frontrunner in energy-driven body contouring solutions, has recently unveiled the newest version of their aesthetic laser platform, Custom CORE™ 8D Multi-Platform Laser, to the global market. Leveraging the company's strong legacy of innovation and excellence, Rejuva Fresh's latest version of Custom CORE™ 8D showcases a sleek contemporary design alongside significant enhancements, delivering expanded treatment options, as well as an intuitively smart user experience. Rejuva Fresh Custom CORE™ 8D delivers a remarkable advancement in patient personalized care. Featuring eight highly sought-after laser technologies, the platform offers an extensive selection of treatments designed to treat all Fitzpatrick skin types and conditions with precision and success. In fact, more than eighty distinct treatments can be performed with the Custom CORE™ 8D. Indeed, this revolutionary technology brought to market by Rejuva Fresh, is far more versatile in its application compared to competing aesthetic laser platforms, which typically offer fewer options. Specifically, Rejuva Fresh's revolutionary platform laser features all of the following options: an IPL/BBL, 3 Wavelength-Diode Laser, Pico-Second Laser, Q-Switch Nanosecond Laser, Long Pulsed YAG Laser, and Erbium 1540nm Fractional Laser, 2940nm Erbium YAG, and 808 Diode Laser. One of the most popular and versatile laser options on Rejuva Fresh Custom CORE™ 8D is the Picosecond Laser, which includes several different attachments and uses ultra-short pulses to create a powerful photoacoustic effects, targeting and breaking down pigment. The Picosecond laser can be successfully used, not only to remove tattoos, but also age spots, acne scars, hyperpigmentation, as well as doing fractional laser skin resurfacing on all skin colors. Practitioners choosing either the Picosecond or Q Switch Nanosecond laser options on the platform benefit from enhanced collagen stimulation and effective pigmentation treatment by focusing on the skin's deeper layers. Meanwhile, the fractional ablative er:YAG laser gently forms tiny perforations in the skin, promoting renewal while protecting nearby tissue to support faster healing. And what about painless hair removal? Yes Custom CORE™ 8D does it superbly. In fact, the 3 wave diode laser features 755nm, 808nm, and 1064nm laser bars, offering painless and lasting hair removal for every skin tone. Excitingly, Rejuva Fresh announced that as part of the upgrade unveiling, that now increased power of 1600W as well as 4 interchangeable spot sizes will be available for their diode laser handpieces. This advancement allows for increased precision and significantly more efficiency compared to traditional diode laser systems that feature only one spot size. No need for bulky handle changes, instead effortlessly change the magnetic tips. The Intense Pulsed Light (IPL)/Broad Band Light (BBL) function has also been upgraded in this recent unveiling. Now the BBL function offers 3 times more energy delivery compared to traditional IPL, as well as 4 interchangeable spot sizes and a facial tip. Rejuva Fresh BBL uses multiple filters to solve different skin concerns, including sun damage, age spots, redness, rosacea, broken blood vessels, fine lines and wrinkles, and uneven pigmentation. With the addition of the flexible spot size the system has become more powerful. While other platform laser systems would stop there, Rejuva Fresh empowers practitioners to offer even more advanced combinations of skin rejuvenation with 2 powerful Erbium laser options. Namely, the 2940nm Er:YAG Laser can be used in ablative mode for skin resurfacing and epidermal renewal, or in coagulation mode to stimulate collagen production and improve skin texture. According to Rejuva Fresh clinical esthetician Niki Wu, 'Integrating an Erbium:YAG 2940 nm laser with BBL represents a highly effective strategy in aesthetic dermatology, targeting a range of skin concerns such as pigmentation, texture irregularities, and overall rejuvenation. The combined use of these technologies enhances treatment efficacy by simultaneously addressing multiple dermatological issues.' Regarding 1540nm Erbium fractional laser, Niki Wu detailed to a group of doctors that the 1540nm laser is a key component of the platform, as it targets deeper skin layers to stimulate collagen production and improve skin texture. 1540nm fractional laser is also very effective to combine with BBL, because the combination addresses both superficial and deeper skin concerns simultaneously. The Custom CORE™ 8D offers a uniquely balanced approach, and with up to a 65% increase in energy*, this exciting new multiplatform offers the robust capabilities of standalone lasers in a single, sophisticated platform. This enhanced energy enables practitioners to address the diverse needs of patients—across different ages, skin types, and treatment goals—and to provide clinically proven treatments for the most in-demand categories, such as skin resurfacing, skin rejuvenation and tightening, hair removal, acne and acne scars, vascular lesions, pigmented lesions, and tattoo removal, to name a few. The new Custom CORE™ 8D is engineered to improve efficiency and user-friendliness, featuring advanced automated capabilities like customizable presets, ergonomically crafted applicators, and more seamless operational functionality than ever. According to Polly Jacobs, founder and CEO of Rejuva Fresh, 'Using several different lights and lasers in one session is the often best way to successfully treat skin conditions, because this approach targets exactly the right skin layers and pigments for better results.' 'Our new Custom CORE™ 8D allows the practitioner to have practically almost the same power as standalone lasers in an all-in-one platform, and to achieve the next level of results with their patients,' she added. The innovative platform is FDA cleared and according to Jacobs: 'After years of development, we are proud to introduce Custom CORE™ 8D to the global market. Combining cutting-edge technology with innovative design, every detail has been meticulously crafted, and we aim to offer a seamless and intelligent user experience' Custom CORE™ 8D raises the bar for functionality, versatility, and performance. This new multiplatform enables professionals to integrate complementary technologies, effectively treating a broad spectrum of aesthetic concerns. It meets the increasing demand for combination procedures that provide longer-lasting results and faster recovery, while significantly improving both practitioner efficiency and patient satisfaction. To help clinics further expand their services and boost visibility, Rejuva Fresh is introducing the new Custom CORE™ 8D Platform alongside its new line of organic serums for their Rejuva Fresh Hydra Spa Infusion Ultra Glow—an exceptionally popular effective branded treatment addressing the highly sought-after skin rejuvenation market. Rejuva Fresh Hydra Spa Infusion Ultra Glow, is a comprehensive treatment that harnesses the skin's natural healing process and leverages the powers of hydro dermabrasion, oxygen therapy, bio stimulation, radio frequency, ultrasound and more to deliver enhanced results. This treatment is arguably more advanced and effective than the traditional Hydra Facial MD as it enables improvement in skin tone and texture as well as hydration deep cleansing and exfoliation. It also serves as a catalyst for collagen renewal and elastin production that continues to work for months post-treatment. *Compared to competing laser platforms such as Harmony XL PRO or Lumenis M22 using specific parameters About Rejuva Fresh, LLC. Rejuva Fresh® is a leading aesthetic equipment developer based in the United States and prioritizes offering powerful state-of-the-art technology combined with top-notch customer support. One of the fastest-growing companies in the aesthetic device industry, Rejuva Fresh offers a wide selection of FDA-cleared systems that address nearly every non-invasive aesthetic and wellness need. Rejuva Fresh's product portfolio provides significant competitive advantages for practices and patients, thanks to their independent business model and strong partnerships with top factories worldwide. Invest in Rejuva Fresh scientifically developed devices, and get comprehensive support from industry experts to achieve optimal clinical results and maximize your return on investment. For more information, visit: Media Contact:Ericson Estrada[email protected] 1-888-436-3120
